Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ana Aza
Deep Analysis of Acquired Resistance to FGFR1 Inhibitor Identifies MET and AKT Activation and an Expansion of AKT1 Mutant Cells
Oncotarget
Oncology
Related publications
MET or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib
Scientific Reports
Multidisciplinary
Transcriptome Profiling of Cervical Cancer Cells Acquired Resistance to Cisplatin by Deep Sequencing
Artificial Cells, Nanomedicine and Biotechnology
Medicine
Biotechnology
Biomedical Engineering
Pharmaceutical Science
A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition
OncoTargets and Therapy
Oncology
Pharmacology
Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
Cancer Research
Cancer Research
Oncology
Activation of the Met Kinase Confers Acquired Drug Resistance in FGFR-targeted Lung Cancer Therapy
Oncogenesis
Cancer Research
Molecular Biology
Combating Acquired TRK Inhibitor Resistance
Cancer Discovery
Oncology
Acquired Resistance to BRAF Inhibition in BRAFV600E Mutant Gliomas
Oncotarget
Oncology
Overexpression of HMGA1 Promotes Anoikis Resistance and Constitutive Akt Activation in Pancreatic Adenocarcinoma Cells
British Journal of Cancer
Cancer Research
Oncology
X-Linked Inhibitor of Apoptosis Protein Inhibits Apoptosis in Inflammatory Breast Cancer Cells With Acquired Resistance to an ErbB1/2 Tyrosine Kinase Inhibitor
Molecular Cancer Therapeutics
Cancer Research
Oncology
